Advice
In the absence of a submission from the holder of the marketing authorisation:
imatinib (Glivec ®) is not recommended for use within NHS Scotland.
Indication under review: treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice89KB (PDF)
Medicine details
- Medicine name:
- imatinib (Glivec)
- SMC ID:
- 923/13
- Indication:
- Treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 October 2013